Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,438 signal articles · 135 in last 24h · 154,019 total before filter · latest 58m ago
135last 24h
869last 7d
144● bullish (7d)
99● bearish (7d)
214publishers
AllMacro207Earnings105M&A125Regulatory22Product21Analyst16
✕ clear all filtersticker: JNJsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight
Associated Press58d agoneutral
Johnson & Johnson proposes $5.5 billion talc settlement to end marathon legal fight

Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer. The drugmaker, which has been fighting talc-related lawsuits for more than a decade, said that the settlement is conditioned on at least 95% of remaining claimants participating. A U.S. bankruptcy court judge denied a $9 billion settlement proposed by company subsidiary Red River Talc last year that would have been one of the biggest mass tort settlements in history.

Johnson & Johnson reaches $5.5 billion baby powder settlement
Reuters Videos58d agoneutralVIDEO
Johnson & Johnson reaches $5.5 billion baby powder settlement

<body><p>STORY: :: New York / July 27, 2026</p><p>:: Dietrich Knauth, Legal Reporter</p><p>"After years of litigation, about 70,000 court cases, and three bankruptcies, Johnson& Johnson has agreed to a $5.5 billion talc settlement. Why are they settling now?&nbsp;</p><p>:: Why did J&J settle after more than a decade of talc litigation?</p><p>"So tens of thousands of women have accused Johnson& Johnson of causing their ovarian cancer. They've alleged that talc-based products, including baby powder, have been contaminated with asbestos and caused them to develop cancer after using these products for a long period of time. Johnson& Johnson has denied that, but these cases have continued to go to trial."</p><p>"And after a couple of attempts to settle these cases through bankruptcy courts, Johnson& Johnson has now reached a deal where they think they can end all of these cases for an overall payment that is about $5.5 billion, although that number could rise depending on how many people participate in the settlement."</p><p>"One of the plaintiff's lawyers told me today that he thinks it's closer to $7 billion. That's not something we're going to know for some time."</p><p>:: Could J&J still face new talc lawsuits in the future?</p><p>:: Johnson & Johnson</p><p>"It does not fully close the door on all future talc litigations. Somebody could develop cancer in the future, decide that they want to file a lawsuit against Johnson& Johnson, because they think that company's product caused their cancer. The reason for that is that there's something called a latency period, which is essentially the delay between when you experience the factors that caused your cancer and when that cancer actually shows up."</p><p>"But, you know, this deal basically gets rid of all of the existing cases. That's the idea."</p><p>J&J reached the settlement after a series of wins in court, including victories in individual trials, successful efforts to disqualify plaintiffs' lawyers from the litigation, and court rulings against experts that plaintiffs had used to prove their cases in court.&nbsp;</p><p>J&J won a significant court victory in the long-running legal battle last week, when a federal judge cast doubt on individual plaintiffs' ability to prove that talc specifically caused their ovarian cancer.</p><p>J&J has long denied that its talc products caused cancer, saying that talc was safe and did not contain asbestos. The company stopped selling talc-based baby powder in the U.S. in 2020, switching to a cornstarch product.</p><p>Before the bankruptcy attempts, J&J had a mixed record in talc trials, with a multibillion verdict in favor of 22 women who said baby powder caused their ovarian cancer. The company won some trials outright and had other verdicts reduced on appeal.</p><p>Unlike the proposed bankruptcy settlements, Monday's agreement applies only to existing claims and does not address future lawsuits.</p></body>

Nasdaq lags on angst over AI spending ahead of earnings reports
Reuters Videos62d agoneutralVIDEO
Nasdaq lags on angst over AI spending ahead of earnings reports

<body><p>STORY: U.S. stocks ended mixed on Friday, with the Dow gaining just under half a percent, the S&P 500 virtually flat and the tech-heavy Nasdaq sliding nearly two-thirds of a percent.</p><p>The S&P 500 technology index underperformed the broader market as chip stocks fell, with Intel dropping nearly 8% despite forecasting quarterly profit and revenue above Wall Street estimates.</p><p>Enthusiasm for the AI trade weakened after Alphabet's announcement earlier this week of a plan to hike capital spending even as it burns cash.</p><p>Richard Reyle, chief investment officer at Questar Capital Partners, said that as a result investors are rotating into what he called "safer parts of the market."</p><p>"Pharmaceuticals have been flying, and that's been, I think, where we see the rotation of the market right now. [FLASH] You look at the iShares, pharmaceutical fund, it's big components that are J&J and Eli Lilly, they're at all-time highs. And they're still relatively not super expensive stocks. So I think that's a place that can be bought and held. And of course, energy. Exxon's going to announce earnings next week. I bet they're going to be a blockbuster and they're going to continue to be because they make money at $60 a barrel. At $100 a barrel, forget about it. They do very well."</p><p>The S&P 500 real estate sector also outperformed during the session. Its leading gainer was Digital Realty Trust, which rallied 11% after it raised its full-year forecast for funds from operations.</p><p>Among other gainers, shares of SLB climbed 11% after the oilfield services firm beat expectations for second-quarter profit.</p><p>Investors now turn their attention to quarterly results next week from Magnificent 7 megacaps Microsoft, Amazon, Meta and Apple.</p></body>

3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
24/7 Wall St.62d agoneutral
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives

Fixed-rate bonds cannot outrun inflation over a 25-year retirement, yet most boomers keep reaching for them anyway. Three companies have raised their dividends for between 50 and 70 consecutive years and may offer a more durable solution, though each carries a hidden transition risk that income investors need to weigh.

Would You Rather Earn $55,000 Today or $110,000 in 20 Years?
24/7 Wall St.67d agoneutral
Would You Rather Earn $55,000 Today or $110,000 in 20 Years?

A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.

The Portfolio That Lets You Ignore Inflation
24/7 Wall St.67d agoneutral
The Portfolio That Lets You Ignore Inflation

The typical American household spent $78,535 in 2024. Headline PCE inflation was running at 4.1% year over year in May 2026, which means the same lifestyle can become thousands of dollars more expensive in a single year. Social Security benefits are rising 2.8% in 2026, but that adjustment may not fully offset the higher cost ... The Portfolio That Lets You Ignore Inflation

Health Care Roundup: Market Talk
The Wall Street Journal70d agoneutral
Health Care Roundup: Market Talk

Find insight on Johnson & Johnson, Rubber Industries, and more in the latest Market Talks covering health care.

Health Care Roundup: Market Talk
The Wall Street Journal71d agoneutral
Health Care Roundup: Market Talk

Find insight on Johnson & Johnson, Roche Holding, Novartis and more in the latest Market Talks covering health care.

Johnson & Johnson Q2 Earnings Call Highlights
MarketBeat71d agoneutral
Johnson & Johnson Q2 Earnings Call Highlights

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.

Earnings, Warsh Testimony: What to Watch the Rest of the Week
The Wall Street Journal71d agoneutral
Earnings, Warsh Testimony: What to Watch the Rest of the Week

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

Bank Earnings, Warsh Testimony: What to Watch This Week
The Wall Street Journal72d agoneutral
Bank Earnings, Warsh Testimony: What to Watch This Week

Investors are gearing up today for the start of a busy bank earnings season. They’ll also be closely watching the latest inflation data and appearances on Capitol Hill over two days by new Federal Reserve Chairman Kevin Warsh.

How Much of Your Social Security Will You Actually Keep After Taxes?
24/7 Wall St.73d agoneutral
How Much of Your Social Security Will You Actually Keep After Taxes?

Social Security benefits come with inflation protection, but the tax formula attached to those benefits does not. For retirees with pensions, IRA withdrawals, taxable investment income, or municipal bond interest, a larger benefit can quietly mean a larger federal tax bill. The result is a tax rule from the 1980s that reaches more retirees every ... How Much of Your Social Security Will You Actually Keep After Taxes?

Bloomberg73d agoneutral
Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says

(Bloomberg) -- A federal appeals court revived lawsuits that claim Kenvue Inc. hid alleged risks that Tylenol could cause autism in children whose mothers took the over-the-counter pain medication while pregnant, a controversy that’s roiled the medical community.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Embraces Australian Retirement System Backed by Larry FinkHormuz Route Open Despite Iran Declaration, Maritime Group SaysOpenAI Engineer’s ‘LOL’ Momen

Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account
24/7 Wall St.73d agoneutral
Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account

An $80,000 salary is not the same as $80,000 of spendable income. Federal withholding, FICA taxes, state income taxes where they apply, and retirement contributions all reduce the number that actually reaches checking. For a single filer in a no-income-tax state, 2026 take-home pay on an $80,000 salary would be about $65,100 before retirement contributions, ... Think You’ll Live on $80,000 a Year? Here’s What Actually Lands in Your Checking Account